Overview

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis. The Extension study was an extension to the 24-month Core study (CFTY720D2301/NCT00289978).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Fingolimod Hydrochloride